SCHEMBL4056560

SCHEMBL4056560

O=C(O)N1CCC(Oc2ccc(Br)cn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.47
HMOX1 P09601 1/20 0.46
NAMPT P43490 11/20 0.45
GPR119 Q8TDV5 2/20 0.44
LIPE Q05469 4/20 0.42
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31370464 0.88 NAMPT (0.57) DGAT1HMOX1NAMPTGPR119LIPE
SCHEMBL18421955 0.83 NAMPT (0.47) NAMPTGPR119LIPE
SCHEMBL5318377 0.83 MMP1 (0.52) NAMPTGPR119LIPEEPHX2
SCHEMBL16973181 0.83 NAMPT (0.45) NAMPTGPR119LIPEEPHX2
SCHEMBL4107104 0.83 LIPE (0.49) NAMPTGPR119LIPEEPHX2
SCHEMBL30427128 0.82 GPR119 (0.66) DGAT1GPR119
SCHEMBL940648 0.82 GPR119 (0.66) DGAT1GPR119
SCHEMBL865755 0.82 GPR119 (0.58) DGAT1NAMPTGPR119
SCHEMBL18423411 0.82 NAMPT (0.47) NAMPTGPR119LIPEEPHX2
SCHEMBL2775875 0.81 HMOX1 (0.60) HMOX1GPR119EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3105225-A1 NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE iTeos Therapeutics (BE) 2016-12-21 EP disclosed
WO-2015121812-A1 NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE ITEOS THERAPEUTICS (BE) 2015-08-20 WO disclosed
EP-2069312-A2 PYRIDIZINONE DERIVATIVES Cephalon, Inc. (US) 2009-06-17 EP disclosed
WO-2008013838-A2 PYRIDIZINONE DERIVATIVES CEPHALON, INC. (US) 2008-01-31 WO disclosed
EP-1676846-A2 Hydantoin derivatives as MMP inhibitors AstraZeneca AB (SE) 2006-07-05 EP disclosed